Up­dat­ed: Eu­ro­pean Com­mis­sion au­tho­rizes No­vavax's up­dat­ed Covid vac­cine

Fol­low­ing the Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) rec­om­men­da­tion, the Eu­ro­pean Com­mis­sion has au­tho­rized for use No­vavax’s adapt­ed Nu­vax­ovid boost­er vac­cine for pre­vent­ing the Omi­cron XBB.1.5 sub­vari­ant of the coro­n­avirus in adults and ado­les­cents 12 years of age and old­er.

The de­ci­sion was based on non-clin­i­cal da­ta show­ing that No­vavax’s up­dat­ed vac­cine in­duced func­tion­al im­mune re­spons­es against the XBB.1.5, XBB.1.16 and XBB.2.3 vari­ants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER